ArticleAmerican journal of translational research2026
Predictive value of baseline hematological parameters for the risk of recurrence in chronic urticaria.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the predictive value of baseline hematological parameters for 1year recurrence risk of chronic urticaria (CU) and to construct a clinically practical prediction model.
methodsThis retrospective study enrolled 155 newly diagnosed CU patients, with an additional 48 independent patients included for external validation. Baseline clinical characteristics and haematological parameters, including total IgE, C-reactive protein (CRP) and D-dimer (DD), were collected. Univariate and multivariate logistic regression analyses were performed to screen independent influencing factors for recurrence. A nomogram prediction model was subsequently established and comprehensively validated using receiver operating characteristic (ROC) curve, calibration curve, decision curve analysis and SHAP analysis. Kaplan-Meier survival curves and Cox regression analysis were adopted to evaluate recurrence-free survival outcomes.
resultsAmong the 155 enrolled patients, 41 developed disease recurrence, corresponding to a recurrence rate of 26.5%. Disease duration (OR = 1.07), total IgE level (OR = 1.01), CRP level (OR = 1.16) and DD level (OR = 1.01) were confirmed as independent predictive factors (all P < 0.05). The combined prediction model achieved an AUC of 0.83 (95% CI: 0.75-0.90), with favorable calibration performance (Hosmer-Lemeshow test, P = 0.446) and stable net clinical benefit within the risk threshold range of 10%-90%. External validation results demonstrated an accuracy of 79.2%, a specificity of 78.4% and a negative predictive value of 93.5%. Patients with disease duration ≥ 20.5 months, total IgE ≥ 173.7 KU/L, CRP ≥ 11.7 mg/L or DD ≥ 142.8 ng/mL had significantly shorter recurrencefree survival time (P < 0.05).
conclusionBaseline disease duration, total IgE, CRP and D-D are independent predictors of 1-year recurrence in CU patients. The constructed nomogram model exhibits reliable predictive performance and good clinical applicability, which can serve as a convenient tool for early recurrence risk stratification and individualized clinical management of CU patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.